PCL Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
31
- Stock Symbol
-
241820
- Share Price
-
$0.95
- (As of Friday Closing)
PCL General Information
Description
PCL Inc is engaged in the development of vitro diagnostics products by SG Cap technology used in immobilizing disease biomarkers. It offers blood testing kit, multiplex antigen detection kits, and ultra-low volume non-contact liquid handling.In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified.
Contact Information
Website
www.pclchip.comCorporate Office
- Room 701, Star Valley
- 99, Digital-ro 9-gil, Geumcheon-gu
- Seoul, 153-777
- South Korea
Corporate Office
- Room 701, Star Valley
- 99, Digital-ro 9-gil, Geumcheon-gu
- Seoul, 153-777
- South Korea
PCL Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.95 | $0.93 | $0.68 - $3.56 | $55M | 59.2M | 1.75M | -$0.24 |
PCL Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 43,296 | 148,330 | 139,028 | 304,641 |
| Revenue | 5,866 | 6,447 | 28,803 | 40,289 |
| EBITDA | (8,496) | (11,983) | 1,103 | (23,415) |
| Net Income | (11,326) | (15,540) | (3,109) | (27,649) |
| Total Assets | 50,679 | 48,262 | 69,631 | 66,634 |
| Total Debt | 12,223 | 14,749 | 24,691 | 25,245 |
PCL Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PCL Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PCL Patents
PCL Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202309912-D0 | Novel biomarker for diagnosis of alzheimer's disease, discovered from blood-derived exosomes, and method for diagnosing alzheimer's disease using same | Pending | 30-Nov-2020 | 00000000000 | |
| GB-2616796-A | Novel biomarker for diagnosis of alzheimer's disease, discovered from blood-derived exosomes, and method for diagnosing alzheimer's disease using same | Pending | 30-Nov-2020 | 000000000 | 0 |
| DE-112021006226-T5 | Novel biomarker for diagnosing alzheimer's disease discovered in a blood-derived exosome and method for diagnosing alzheimer's disease using the same | Pending | 30-Nov-2020 | 00000000000 | 0 |
| JP-2023551327-A | Novel alzheimer's disease diagnostic biomarker discovered from blood-derived exosomes and alzheimer's disease diagnostic method using the same | Pending | 30-Nov-2020 | 00000000000 | |
| US-20240053365-A1 | Novel biomarker for diagnosis of alzheimer's disease, discovered from blood-derived exosomes, and method for diagnosing alzheimer's disease using same | Pending | 30-Nov-2020 | G01N33/6896 |
PCL Executive Team (2)
| Name | Title | Board Seat |
|---|---|---|
| Kim Soyoun | Founder & Chief Executive Officer |
PCL Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PCL Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PCL ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
20.02 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,784
Rank
Percentile
Technology Hardware
Industry
00 of 577
Rank
Percentile
Electronics Equipment
Subindustry
00 of 123
Rank
Percentile
PCL FAQs
-
When was PCL founded?
PCL was founded in 2008.
-
Who is the founder of PCL?
Kim Soyoun is the founder of PCL.
-
Who is the CEO of PCL?
Kim Soyoun is the CEO of PCL.
-
Where is PCL headquartered?
PCL is headquartered in Seoul, South Korea.
-
What is the size of PCL?
PCL has 31 total employees.
-
What industry is PCL in?
PCL’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is PCL a private or public company?
PCL is a Public company.
-
What is PCL’s stock symbol?
The ticker symbol for PCL is 241820.
-
What is the current stock price of PCL?
As of 13-Sep-2024 the stock price of PCL is $0.95.
-
What is the current market cap of PCL?
The current market capitalization of PCL is $55M.
-
What is PCL’s current revenue?
The trailing twelve month revenue for PCL is $5.87M.
-
What is PCL’s annual earnings per share (EPS)?
PCL’s EPS for 12 months was -$0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
